Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
US biotechs thinking twice about licensing drugs to Europe
U.S. biotechs are increasingly reluctant to license their drugs to European partners in order to avoid becoming a target of the Trump administration.
James Waldron
Sep 26, 2025 8:09am
Merck opts in on Evaxian's preclinical vaccine candidate
Sep 25, 2025 7:00am
Biopharma biobucks decline, while upfront deal payments rise
Sep 24, 2025 11:30am
Cyclerion emerges from latest pivot as neuro biotech
Sep 24, 2025 4:15am
Angelini signs $550M-plus neuro pact with South Korean biotech
Sep 22, 2025 1:47pm
VectorY pens $1.2B pact to use Shape's brain-penetrating capsid
Sep 18, 2025 9:25am
